Clinical trials: Systemic Lupus Erythematosus
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)
The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with…
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases
- Trial name
- QSIT (NCT07221565)
- Testing
- Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Low-Dose Naltrexone (LDN)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Truway Health, Inc.
Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS)
SPOCS is an international, multicenter, prospective observational cohort study with bi-annual study visits over a 3-year follow-up designed to systematically describe the comprehensive SLE patient-journey regarding clinical…
- Trial name
- SPOCS (NCT03189875)
- Testing
- Standard of Care
- Where
- 135 sites in United States, Australia and 6 more
- Volunteers
- 830 people
- Sponsor
- AstraZeneca
Systemic Lupus Erythematosus, Sjögren's Disease
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07873931
- Testing
- BMS-986553
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Systemic Lupus Erythematosus
Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
PRIMULA Preg (Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users) is a prospective, observational cohort study designed to evaluate the association between anifrolumab exposure during pregnancy…
- Trial name
- PRIMULA_Preg (NCT06659029)
- Testing
- Anifrolumab
- Where
- United States
- Volunteers
- 442 people
- Sponsor
- AstraZeneca
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
In this study, researchers will learn more about a study drug called BIIB059 (litifilimab) in participants with cutaneous lupus erythematosus (CLE).
- Trial name
- AMETHYST LTE (NCT06044337)
- Testing
- BIIB059 (litifilimab)
- Where
- 104 sites in United States, Argentina and 23 more
- Volunteers
- 306 people
- Sponsor
- Biogen
Lupus Erythematosus, Systemic
Evaluation of the Influence of Food Regimen on Oshadi D Absorption
The study will be a non-randomized, open label, single dose, placebo control, single center, and single arm study in healthy subjects.
- Trial name
- NCT01327352
- Testing
- Oshadi D
- Where
- Israel
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Oshadi Drug Administration
Systemic Lupus Erythematosus, Lupus Nephritis
An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus
The study is intended to assess safety, efficacy and cellular kinetics of YTB323 treatment in participants with severe refractory systemic lupus erythematosus.
- Trial name
- NCT05798117
- Testing
- YTB323
- Where
- 10 sites in Australia, France and 3 more
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Lupus Nephritis
BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis
The primary objective of the study is to assess the efficacy of BIIB023 as an add-on treatment to background therapy compared with placebo in combination with background therapy in the treatment of participants with active…
- Trial name
- ATLAS (NCT01499355)
- Testing
- BIIB023, mycophenolate mofetil, oral corticosteroids
- Where
- 58 sites in United States, Argentina and 19 more
- Volunteers
- 276 people
- Sponsor
- Biogen
Lupus Nephritis
Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis
This study is designed to compare the safety and efficacy of Mycocep Capsules (Mycophenolate Mofetil) and a marketed Azathioprine formulation, Imuran Azathioprine Tablets, in the maintenance therapy of lupus nephritis.
- Trial name
- NCT02949349
- Testing
- Mycophenolate mofetil, Azathioprine, Prednisolone
- Volunteers
- 32 people
- Sponsor
- Genovate Biotechnology Co., Ltd.,
Systemic Lupus Erythematosus
Study of CD19 CAR-T Therapy for Refractory SLE
This is an investigator-initiated trial aimed at assessing the safety and efficacy of PTOC1 cells Injection in the treatment of refractory systemic lupus erythematosus.
- Trial name
- NCT07403097
- Testing
- PTOC1
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Systemic Lupus Erythematosus
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus
This is a multicenter, randomized, double-blind, placebo-controlled, sequential rising single-dose study in which approximately 56 subjects with SLE will be enrolled in 7 dosing cohorts
- Trial name
- NCT02391259
- Testing
- AMG 557
- Where
- 13 sites in United States, United Kingdom
- Volunteers
- 57 people
- Sponsor
- Amgen
Lupus Erythematosus, Systemic
Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)
This is a multicenter, double-blind, Phase 2b, long-term extension (LTE) to the ADDRESS II core trial (EMR 700461-023) (NCT01972568), to evaluate long-term safety and tolerability of atacicept in participants with systemic lupus…
- Trial name
- NCT02070978
- Testing
- Atacicept 75 mg, Atacicept 150 mg
- Where
- 84 sites in United States, Argentina and 15 more
- Volunteers
- 253 people
- Sponsor
- EMD Serono
Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic…
- Trial name
- NCT07355218
- Testing
- Enpatoran, Standard of care (SoC)
- Where
- 57 sites in United States, Australia and 15 more
- Volunteers
- 202 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Systemic Lupus Erythematosus
A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)
The purpose of the study is to assess the Safety, Tolerability, PK/PD and preliminary Efficacy of ICP-022 in Subjects with Systemic Lupus Erythematosus (SLE)
- Trial name
- NCT04305197
- Testing
- ICP-022
- Where
- 11 sites in China
- Volunteers
- 60 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Systemic Lupus Erythematosus
A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus.
The purpose of the study is to evaluate the safety and tolerability of MEDI-545 in Japanese adult SLE patients. This will be done by collecting the data from 3 cohorts of IV doses and 1 cohort of SC doses.
- Trial name
- NCT01031836
- Testing
- MEDI-545, MEDI-545 600
- Where
- 7 sites in Japan
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and…
- Trial name
- NCT06570798
- Testing
- Inebilizumab, Blinatumomab
- Where
- 58 sites in United States, Australia and 8 more
- Volunteers
- 220 people
- Sponsor
- Amgen
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Systemic Lupus Erythematosus
Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
The purpose of the study is to assess the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with systemic lupus erythematosus (SLE).
- Trial name
- NCT03742037
- Testing
- Cenerimod 0.5 mg, Cenerimod 1 mg, Cenerimod 2 mg
- Where
- 148 sites in United States, Bulgaria and 22 more
- Volunteers
- 427 people
- Sponsor
- Viatris Innovation GmbH
Systemic Lupus Erythematosus
Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)
To evaluate the efficacy and safety of CM313(SC) injection in systemic lupus erythematosus(SLE)
- Trial name
- NCT06791772
- Testing
- CM313 injection
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Keymed Biosciences Co.Ltd
Systemic Lupus Erythematosus
GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia
The purpose of this study is to evaluate the efficacy and safety of belimumab in addition to standard therapy compared to placebo in subjects in Northeast Asia with systemic lupus erythematosus (SLE) over a 52 week period.
- Trial name
- NCT01345253
- Testing
- Belimumab
- Where
- 47 sites in China, Japan and 1 more
- Volunteers
- 709 people
- Sponsor
- GlaxoSmithKline